Comparison between Topical Beta-Sitosterol and Topical Hirudin in Management of Facial Burns

Ang E.S., Lee S.T., Gan C.S., et al.: The role of alternative
therapy in the management of partial thickness burns of
the face-experience with the use of moist exposed burn
ointment (MEBO) compared with silver sulphadiazine.
Ann. Acad. Med. Singap, 29 (1): 7-10, 2000.
2- Azizkhan R.G., Azizkhan J.C., Zetter B.R. and Folkman
J.: Mast cell heparin stimulates migration of capillary endothelial
cells in vitro. J. Exp. Med., 152 (4): 931-944,
1980.
3- Buderer N.M.: Statistical methodology: I. Incorporating
the prevalence of disease into the sample size calculation
for sensitivity and specificity. Acad. Emerg. Med., 3 (9):
895-900, 1996.
4- Chae J.K., Kim J.H., Kim E.J. and Park K.: Values of a Patient
and Observer Scar Assessment Scale to Evaluate the
Facial Skin Graft Scar. Ann. Dermatol., 28 (5): 615-623,
2016.
5- Clark C., Ledrick D. and Moore A.: Facial Burns. In: Stat-
Pearls. Treasure Island (FL): StatPearls Publishing, July 8,
2021.
6- Demling R.H. and Pomposelli J.J.: In: Surgical Infections.
Meakins J.L., editor. New York: Scientific American Medicine,
369-373, 1994.
7- Demling R.H., Wong C., Jin L.J., Hechtman H., Lalonde
C. and West K.: Early lung dysfunction after major burns:
Role of edema and vasoactive mediators. J. Trauma, 25
(10): 959-966, 1985.
8- El-Hadidy M.R., El-Hadidy A.R., Bhaa A., Asker S.A.
and Mazroa S.A.: Role of epidermal stem cells in repair
of partial-thickness burn injury after using Moist Exposed
Burn Ointment (MEBO(®)) histological and immunohistochemical
study. Tissue Cell, 46 (2): 144-151, 2014.
9- Fawzy Ahmed Hamza, Ahmed Abu-Elsoud Salim and
Hossam Nasr Rizk: “Evaluation of the Effect of Topical
Heparin on the Treatment of Facial Burn”. Al-Azhar International
Medical Journal, 1 (2): 198-202, 2020.
10- Gojowy D., Kauke M., Ohmann T., Homann H.H. and
Mannil L.: Early and late-recorded predictors of health-related
quality of life of burn patients on long-term follow-
up. Burns, 45 (6): 1300-1310, 2019.
11- Griffin J.E. and Johnson D.L.: Management of the maxillofacial
burn patient: Current therapy. J. Oral Maxillofacial
Surg., 63 (2): 247-252, 2005.
12- Gupta A., Gupta P. and Verghese T.: Role of topical heparin
in the management of burns. Experience in a district
government hospital of Karnataka in South India, 2 (3):
111-112, 2015.
13- Hoogewerf C.J., Hop M.J., Nieuwenhuis M.K., Oen I.M.,
Middelkoop E. and Van Baar M.E.: Topical treatment
for facial burns. Cochrane Database Syst. Rev., 7 (7):
CD008058, 2020. Published 2020 Jul 29.
14- ISBI Practice Guidelines Committee: Steering Subcommittee;
Advisory Subcommittee. ISBI Practice Guidelines
for Burn Care. Burns, 42 (5): 953-1021, 2016.
15- ISBI Practice Guidelines Committee: Advisory Subcommittee;
Steering Subcommittee. ISBI Practice Guidelines
for Burn Care, Part 2. Burns, 44 (7): 1617-1706, 2018.
16- Draaijers L.J., Tempelman F.R., Botman Y.A., Tuinebreijer
W.E., Middelkoop E., Kreis R.W., et al.: The patient
and observer scar assessment scale: A reliable and feasible
for scar evaluation. Plast Reconstr Surg., 113 (7): 1960-
1967, 2004.
17- Maciag T., Mehlman T., Friesel R. and Schreiber A.B.:
Heparin binds endothelial cell growth factor, the principal
endothelial cell mitogen in bovine brain. Science, 225
(4665): 932-935, 1984.
18- Manzoor S., Khan F.A., Muhammad S., et al.: Comparative
study of conventional and topical heparin treatment in
second degree burn patients for burn analgesia and wound
healing. Burns, 45 (2): 379-386, 2019.
19- Markwardt F.: The development of hirudin as an antithrombotic
drug. Thromb. Res., 74: 1-23, 1994.
20- Masoud M., Wani A.H. and Darzi M.A.: Topical heparin
versus conventional treatment in acute burns: A comparative
study. Indian J. Burns, 22: 43-50, 2014.
21- Mertens D.M., Jenkins M.E. and Warden G.D.: Outpatient
burn management. Nurs. Clin. North. Am., 32 (2): 343-
364, 1997.
22- Moher D., Schulz K.F. and Altman D.G.: The CONSORT
Statement. Revised recommendations for improving the
quality of reports of parallel-group randomized trials. Lancet,
357 (9263): 1191-1194, 2001.
23- Nowak G.: Pharmacology of recombinant hirudin. Semin.
Thromb. Hemost., 28: 415-423, 2002.
24- Palmieri T.L., Przkora R., Meyer W.J. and Carrougher
G.J.: Measuring burn injury outcomes. Surg. Clin. North.
Am.,94 (4): 909-916, 2014.
25- Saliba M.J. Jr., Dempsey W.C. and Kruggel J.L.: Large
burns in humans. Treatment with heparin. JAMA, 225 (3):
261-269, 1973.
26- Saliba Jr., M.J.: “Heparin In Burns Protocol.” Internet
website: http://www. salibaburnsinstitute. org and ProEgypt,
J. Plast. Reconstr. Surg., January 2024 15
ceedings, Heparin Effects In Burns International Symposium,
2000.
27- Saliba M.J. Jr. and Saliba R.J.: Heparin in burns. Dose
related and dose dependent effects. Thromb Diath Haemorrh.,
33 (1): 113-123, 1975.
28- Teles G.G. do A. and Bastos J.A.: Treatment of superficial
Second- degree burn of face and neck with topical heparin.
A comparative, prospective and randomized study. Revista
Brasileira de Cirurgia Plástica. SciELO Brasil, 27: 383-
386, 2012.
29- Venkatachalapathy T.S.: A comparative Study of Pediatric
Thermal Burns Treated with Topical Heparin and Without
Heparin. Indian Journal of Surgery, 76 (4): 282-287, 2014.
30- Venakatachalapathy T.S., Mohan Kumar S. and Saliba
M.J.: A comparative study of burns treated with topical
heparin and without heparin. Annals of Burns and Fire
Disasters, 20 (4): 189-198, 2007.
31- von Arx T., Tamura K., Yukiya O. and Lozanoff S.: The
Face. A Vascular Perspective. A literature review. Swiss
Dent J., 128 (5): 382-392,